Moving towards individualized medicine with pharmacogenomics.

PubWeight™: 2.99‹?› | Rank: Top 1%

🔗 View Article (PMID 15164072)

Published in Nature on May 27, 2004

Authors

William E Evans1, Mary V Relling

Author Affiliations

1: Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. william.evans@stjude.org

Articles citing this

Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95

Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A (2009) 3.01

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52

CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20

Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood (2011) 2.04

Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol (2015) 1.84

Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82

Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med (2013) 1.78

Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78

Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel (2010) 1.74

Pharmacogenomics in the clinic. Nature (2015) 1.71

Label-free molecular imaging of atherosclerotic lesions using multimodal nonlinear optical microscopy. J Biomed Opt (2007) 1.53

Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol (2006) 1.40

In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med (2008) 1.37

Systems pharmacology and genome medicine: a future perspective. Genome Med (2009) 1.26

Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics (2009) 1.16

Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate. J Biopharm Stat (2011) 1.16

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics (2009) 1.15

Genome-wide scan for signatures of human population differentiation and their relationship with natural selection, functional pathways and diseases. PLoS One (2009) 1.14

Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res (2010) 1.13

Genetic-based prediction of disease traits: prediction is very difficult, especially about the future. Front Genet (2014) 1.12

Translational integrity and continuity: personalized biomedical data integration. J Biomed Inform (2008) 1.09

Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci (2005) 1.04

Acute lymphoblastic leukemia: introduction. Semin Hematol (2009) 1.02

Influence of catechol-O-methyltransferase (COMT) gene polymorphisms in pain sensibility of Brazilian fibromialgia patients. Rheumatol Int (2010) 0.98

Personal genomes, quantitative dynamic omics and personalized medicine. Quant Biol (2013) 0.98

Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J (2006) 0.96

Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PLoS One (2012) 0.94

Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood (2005) 0.93

Precision medicine: from pharmacogenomics to pharmacoproteomics. Clin Proteomics (2016) 0.92

Deciphering next-generation pharmacogenomics: an information technology perspective. Open Biol (2014) 0.91

Risk, reward, and the double-edged sword: perspectives on pharmacogenetic research and clinical testing among Alaska Native people. Am J Public Health (2013) 0.91

Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. Biomaterials (2012) 0.90

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol (2006) 0.90

Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett (2006) 0.89

Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol (2009) 0.88

Pharmacogenetics and the print media: what is the public told? BMC Med Genet (2015) 0.88

Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. Cancer (2012) 0.88

Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome? Br J Clin Pharmacol (2015) 0.87

An inconvenient truth: recognizing individual differences in arteriogenesis. Circ Res (2008) 0.86

A traditional Chinese medicine versus Western combination therapy in the treatment of rheumatoid arthritis: two-stage study protocol for a randomized controlled trial. Trials (2011) 0.86

Why personalized medicine will fail if we stay the course. Per Med (2012) 0.86

BIOPHYSICAL PROPERTIES OF NUCLEIC ACIDS AT SURFACES RELEVANT TO MICROARRAY PERFORMANCE. Biomater Sci (2014) 0.85

A taste of individualized medicine: physicians' reactions to automated genetic interpretations. J Am Med Inform Assoc (2013) 0.84

Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics (2009) 0.84

High-risk childhood acute lymphoblastic leukemia. Clin Lymphoma Myeloma (2009) 0.84

Mutant huntingtin alters cell fate in response to microtubule depolymerization via the GEF-H1-RhoA-ERK pathway. J Biol Chem (2010) 0.84

The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia (2009) 0.83

Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial. Acta Diabetol (2015) 0.83

Drug interactions in childhood cancer. Lancet Oncol (2010) 0.83

Practical considerations in genomic decision support: The eMERGE experience. J Pathol Inform (2015) 0.82

Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in Emiratis. PLoS One (2011) 0.82

PharmGED: Pharmacogenetic Effect Database. Nucleic Acids Res (2006) 0.82

Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmgenomics Pers Med (2012) 0.82

Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9. J Med Chem (2007) 0.82

Indirect readout in drug-DNA recognition: role of sequence-dependent DNA conformation. Nucleic Acids Res (2007) 0.82

Personalized drug therapy; the genome, the chip and the physician. Br J Clin Pharmacol (2005) 0.81

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res (2014) 0.80

Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine. Int J Mol Sci (2015) 0.80

The Finnish Cardiovascular Study (FINCAVAS): characterising patients with high risk of cardiovascular morbidity and mortality. BMC Cardiovasc Disord (2006) 0.80

Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics (2009) 0.79

Application of personalized medicine to chronic disease: a feasibility assessment. Clin Transl Med (2013) 0.79

Acute lymphoblastic leukemia and developmental biology: a crucial interrelationship. Cell Cycle (2011) 0.79

Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis. Medicine (Baltimore) (2016) 0.79

Detection and prevention of prescriptions with excessive doses in electronic prescribing systems. Eur J Clin Pharmacol (2007) 0.79

Human cancer classification: a systems biology- based model integrating morphology, cancer stem cells, proteomics, and genomics. J Cancer (2011) 0.78

Studying synthetic lethal interactions in the zebrafish system: insight into disease genes and mechanisms. Dis Model Mech (2011) 0.78

TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer (2009) 0.78

[Proteome analysis--basis for individualized pancreatic carcinoma therapy?]. Internist (Berl) (2006) 0.78

Pharmacogenomic technologies: a necessary "luxury" for better global public health? Global Health (2011) 0.78

Stochastic modeling of systems mapping in pharmacogenomics. Adv Drug Deliv Rev (2013) 0.78

An Altered Treatment Plan Based on Direct to Consumer (DTC) Genetic Testing: Personalized Medicine from the Patient/Pin-cushion Perspective. J Pers Med (2012) 0.78

Pharmacogenetics of ophthalmic topical beta-blockers. Per Med (2008) 0.77

Predose and Postdose Blood Gene Expression Profiles Identify the Individuals Susceptible to Acetaminophen-Induced Liver Injury in Rats. PLoS One (2015) 0.77

Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clin Exp Immunol (2009) 0.77

Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77

Ethical and practical challenges to studying patients who opt out of large-scale biorepository research. J Am Med Inform Assoc (2013) 0.77

Multiplexed fluorescence imaging of tumor biomarkers in gene expression and protein levels for personalized and predictive medicine. Curr Mol Med (2009) 0.76

Promoter polymorphisms in the β-2 adrenergic receptor are associated with drug-induced gene expression changes and response in acute lymphoblastic leukemia. Clin Pharmacol Ther (2010) 0.76

Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa. Genet Mol Biol (2014) 0.76

Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic. Front Genet (2015) 0.75

Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. EXCLI J (2017) 0.75

Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine. Clin Kidney J (2012) 0.75

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics (2016) 0.75

Preappointment testing for BRAF/KIT mutation in advanced melanoma: a model in molecular data delivery for individualized medicine. Hum Pathol (2014) 0.75

Beyond Genetics-Stratified and Personalised Medicines Using Multiple Parameters. Pharmaceuticals (Basel) (2010) 0.75

Personalized medicine and the clinical laboratory. Einstein (Sao Paulo) (2014) 0.75

Towards an Oncology Database (ONCOD) Using a Warehousing Approach. AMIA Jt Summits Transl Sci Proc (2012) 0.75

Aptamer-based Field-Effect Biosensor for Tenofovir Detection. Sci Rep (2017) 0.75

CYP2D6 allele distribution in Macedonians, Albanians and Romanies in the Republic of Macedonia. Balkan J Med Genet (2016) 0.75

Radiation induced esophageal adenocarcinoma in a woman previously treated for breast cancer and renal cell carcinoma. BMC Res Notes (2012) 0.75

Effect of Sri Lankan traditional medicine and Ayurveda on Sandhigata Vata (osteoarthritis of knee joint). Ayu (2015) 0.75

[Health economic aspects of a stratified medicine for rheumatoid arthritis]. Z Rheumatol (2013) 0.75

ABCB1 genetic variants in leukemias: current insights into treatment outcomes. Pharmgenomics Pers Med (2017) 0.75

Structural and energetic insights into sequence-specific interaction in DNA-drug recognition: development of affinity predictor and analysis of binding selectivity. J Mol Model (2012) 0.75

Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets. J Comput Aided Mol Des (2007) 0.75

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment. BMC Med Genet (2017) 0.75

Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2017) 0.75

Articles by these authors

(truncated to the top 100)

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12

Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16

Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71

Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol (2011) 3.05

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82

Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52

Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol (2008) 2.51

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39

Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA (2007) 2.38

Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37

Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20

Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96

Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet (2005) 1.94

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90

Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89

Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88

Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85

Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst (2013) 1.81

Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc (2013) 1.80

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood (2014) 1.80

Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet (2003) 1.79

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood (2008) 1.79

Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol (2003) 1.75

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol (2013) 1.75

Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood (2011) 1.67

PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66

Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol (2014) 1.58

Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell (2005) 1.58

Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer (2010) 1.54

Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.53

Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood (2006) 1.52

Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52

Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol (2012) 1.52

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet (2014) 1.49

Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest (2005) 1.46

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2011) 1.46

Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet (2013) 1.45

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42

Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer (2008) 1.42

ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2012) 1.39

In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med (2008) 1.37

Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med (2011) 1.34

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30

Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics (2013) 1.30

PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27

A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res (2009) 1.25

A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2008) 1.18

Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood (2012) 1.17

Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol (2010) 1.16

Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos (2008) 1.12

Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood (2003) 1.10

Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol (2014) 1.10

Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood (2006) 1.10

De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood (2002) 1.08

Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol (2010) 1.07

Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2008) 1.05

The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst (2008) 1.04

Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03

Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics (2002) 1.03

A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol (2002) 1.02

Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum Mol Genet (2007) 1.01

HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin Chem (2002) 1.01

Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer (2012) 0.99

Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood (2004) 0.98

A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics (2004) 0.96

A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res (2007) 0.96

Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J Clin Oncol (2014) 0.96

CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. J Clin Oncol (2008) 0.96

Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res (2007) 0.95

Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer (2008) 0.95

Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada. Environ Health Perspect (2007) 0.94

Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer (2005) 0.94

Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood (2005) 0.93

Evidence for age as a modifier of genetic associations for lipid levels. Ann Hum Genet (2011) 0.92

Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. Int J Data Min Bioinform (2011) 0.91

Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2002) 0.91

Thiopurine pathway. Pharmacogenet Genomics (2010) 0.90

High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med (2013) 0.90

Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am J Pathol (2013) 0.89

Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett (2006) 0.89

Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics (2014) 0.89